Biomarkers are generally used as diagnostic and prognostic tools in clinical practice, but are not yet available for neuropathies. Studies now suggest that neural protein levels in serum and cerebrospinal fluid reflect axonal damage and predict poor outcome in patients with immune-mediated neuropathy, although validation studies are needed to define their clinical relevance.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
van Doorn, P. A., Ruts, L. & Jacobs, B. C. Clinical features, pathogenesis, and treatment of Guillain–Barré syndrome. Lancet Neurol. 7, 939–950 (2008).
Brettschneider, J., Petzhold, A., Süssmuth, S. & Tumani, H. Cerebrospinal fluid biomarkers in Guillain–Barré syndrome—where do we stand? J. Neurol. 256, 3–12 (2009).
Plomp, J. J. & Willison, H. J. Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction. J. Physiol. 587 (Pt 16), 3979–3999 (2009).
Hadden, R. D. et al. Electrophysiological classification of Guillain–Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain–Barré Syndrome Trial Group. Ann. Neurol. 44, 780–788 (1998).
Petzold, A. et al. CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain–Barré syndrome. Muscle Nerve 40, 42–49 (2009).
Notturno, F., Capasso, M., Delauretis, A., Carpo, M. & Uncini, A. Glial fibrillary acidic protein as a marker of axonal damage in chronic neuropathies. Muscle Nerve 40, 50–54 (2009).
Quattrini, A. et al. Beta 4 integrin and other Schwann cell markers in axonal neuropathy. Glia 17, 294–306 (1996).
Notturno, F., Caporale, C. M., de Lauretis, A. & Uncini, A. Glial fibrillary acidic protein: a marker of axonal Guillain–Barré syndrome. Muscle Nerve 38, 899–903 (2008).
Petzold, A. et al. Glial fibrillary acidic protein in Guillain-–Barré syndrome: methodological issues. Muscle Nerve 39, 711–712 (2009).
van Koningsveld, R. et al. A clinical prognostic scoring system for Guillain–Barré syndrome. Lancet Neurol. 6, 589–594 (2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Jacobs, B., Willison, H. Biomarkers for axonal damage in immune-mediated neuropathy. Nat Rev Neurol 5, 584–585 (2009). https://doi.org/10.1038/nrneurol.2009.161
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2009.161
